Sana Biotechnology (SANA) Long-Term Debt Issuances (2024 - 2025)
Sana Biotechnology (SANA) reported Long-Term Debt Issuances of -$89000.0 for Q4 2025, down 58.93% on a YoY basis from -$216695.7 in Q4 2024, and down 2.3% sequentially from -$87000.0 in Q3 2025.
Sana Biotechnology (SANA) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Sana Biotechnology (SANA) has 2 years of Long-Term Debt Issuances data on file, last reported at -$89000.0 in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Debt Issuances fell 58.93% year-over-year to -$89000.0; the trailing twelve-month figure through Dec 2025 stood at -$60000.0 (changed N/A YoY), and the FY2025 full-year result was -$347000.0, down 104.48% from the prior year.
- Long-Term Debt Issuances retreated to -$89000.0 in Q4 2025, from -$87000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $172000.0 in Q3 2024 to a low of -$89000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Sana Biotechnology | 888.71 Mn | 888.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -89,000.00 |
| Dec 31, 2025 | -89,000.00 |
| Sep 30, 2025 | -87,000.00 |
| Sep 30, 2025 | -87,000.00 |
| Dec 31, 2024 | -56,000.00 |
| Dec 31, 2024 | -56,000.00 |
| Sep 30, 2024 | 172,000.00 |
| Sep 30, 2024 | 172,000.00 |